Innovative cell therapies for the treatment of kidney disease

Butterfly's novel cell based therapies tackle one of the world’s major healthcare challenges

Butterfly Biosciences develops novel, cell based therapies that ameliorate kidney function thereby allowing patients to live better, more productive and higher quality lives. Our innovative, personalized therapies have the potential to treat chronic diseases (such as Lupus and Chronic Kidney Disease) providing new and exciting paradigms for healthcare worldwide.

~ 0

Worldwide estimated number of dialysis patients

people on waiting list for a Kidney transplant in the US

~ 0

US patients on dialysis at annual cost nearly $100,000 p/patient

Butterfly & Lupus

Lupus is a serious disease most often diagnosed in young women age 15 to 44. While the cause is unknown, it is a complex disease that is difficult to diagnose, treat, and defeat.

Lupus nephritis (LN) affects around 50% of Lupus patients, based on clinical and laboratory findings. The main goal of the management of LN is to avoid chronic kidney disease (CKD). Current treatment strategies remain unsatisfactory in terms of complete renal response, prevention of relapses, CKD, and progression to end-stage kidney disease.

High-quality solution for a wide network

Cell therapies are very expensive and the requirements for acceptance in clinical trials leave many unable to get the care that can improve and extend their lives.

POCare centers are processing facilities dedicated to cell and gene therapies placed in medical/research institutions with the goal to significantly enhance the accessibility of advanced cell and gene therapies by lowering the processing and delivery costs and eliminating the logistical and administrative challenges related to centralized production of such therapies.

Butterfly BioSciences Scientific Advisory Experts

The Butterfly Biosciences Scientific Advisory Experts is made of leading scientists, professors and researchers, dedicated to exploring cell therapies for patient health improvement.

Prof. Chaya Brodie

Professor Chaya Brodie maintains research programs at Henry Ford Hospital in Detroit and Bar-Ilan University in Israel.

Prof. Eitan Friedman

MD. PhD, Director and founder of the The Suzanne Levy-Gertner Oncogenetics Unit. MD graduate from the Sackler School of Medicine, TAU; PhD from the Karolinska Institutet, Sweden.

Prof. Yosef Haviv

Director of Nephrology at Soroka University Medical Center, Beer Sheva, ISRAEL

Prof. Lilach O. Lerman

Mayo Foundation for Medical Education and Research, MMS · Division of Nephrology and Hypertension. MD.

Prof. Haim Putterman

Director of the Einstein Federation of Clinical Immunology Societies Centre of Excellence and a member of the American Society for Clinical Investigation, the American College of Rheumatology and the American Association of Immunologists.